Mesothelioma Cancer Resources Blog

A healthy immune system is one of the critical components for staving off cancer, but when the immune system is suppressed cancer cells can run amok. However, researchers have been stymied when it comes to distinguishing just which blood cells help the cancer cells beat back the immune system and take over. Now, researchers report …

The anti-cancer compound Gilotrif (afatinib) was granted approval by the U.S. Food and Drug Administration in July 2013 for patients with late stage non-small cell lung cancer whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations. Now, the maker of the drug reports data from two independent Phase III clinical trials …

Last week, mesothelioma nurse, Lisa Hyde-Barrett reported on “super-responders” –  patients who have exceptional results in clinical trials. Researchers are using genome sequencing on these patients in hopes of finding a common genetic mutation that may result in additional patients having the same positive responses to the novel treatments. But genetic testing is not limited …